Sanofi reports results from two Phase 3 trials evaluating Dupixent
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
- First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the Treatment of.....»»
Biogen"s Retinal Disease Gene Therapy Flunks Mid-Stage Study
Biogen Inc (NASDAQ: BIIB) has announced topline results from the Phase 2/3 XIRIUS study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients w.....»»
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results
VICTORIA, BC, May 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug deli.....»»
Diffusion Pharmaceuticals reports results from Phase 1b study of TSC
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Humanigen reports publication of results from Phase 3 COVID-19 lenzilumab trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
BioLineRx reports "positive" results from GENESIS Phase 3 trial of motixafortide
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sarepta reports clinical results from Phase 2 MOMENTUM study of SRP-5051
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Pluristem reports Phase I results studying PLX-R18 in humans
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board.....»»
Sanofi reports Phase 3 MELODY trial reached primary endpoint
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
I-MAB reports positive Phase 2 results for olamkicept in ulcerative colitis
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bristol-Myers reports "positive" results from Phase 3 CheckMate -648 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Clene to release results from four Phase 2 trials in 2H, says Roth Capital
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Humanigen reports Phase 3 results demonstrating lenzilumab improves survival
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect
Immunic Inc’s (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. read more.....»»
BrainStorm reports "positive" data in Phase 2 study evaluating NurOwn
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Incyte"s Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients
Incyte Corporation NASDAQ: INCY) announced results from the Phase 3 DEVENT study evaluating two doses of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients read more.....»»
Ampio reports "preliminary positive results" in AP-014 Phase I trial of Ampion
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
AC Immune reports topline AC1-24 Phase 1b immunogenicity, safety results
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Inhibrx"s INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a pre.....»»